Form 4: Fulgent Genetics CFO Sells Shares for Tax Obligations

Fulgent Genetics' CFO and Treasurer, Paul Kim, disposed of 1,131 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Paul Kim, the Chief Financial Officer and Treasurer of Fulgent Genetics, Inc. (FLGT), reported a disposition of common stock.
• The transaction involved the sale of 1,131 shares of common stock at a price of $28.52 per share.
• This disposition occurred on December 1, 2025, and was made pursuant to a Rule 10b5-1 pre-planned trading arrangement.
• The shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) granted to Mr. Kim on February 28, 2022.
• Following this transaction, Paul Kim beneficially owns 331,150 shares of Fulgent Genetics common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary sale of shares by an executive to cover tax obligations upon RSU vesting. This is a neutral event and does not reflect positively or negatively on the company's operational or financial performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This is a routine insider transaction related to executive compensation and tax obligations, which is common across various industries for publicly traded companies with RSU programs. It does not reflect specific industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's outlook or company fundamentals.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale of shares by the CFO to satisfy tax withholding obligations upon the vesting of restricted stock units. This type of insider transaction, especially when executed under a 10b5-1 plan, does not typically reflect management's sentiment about the company's future prospects and therefore does not warrant a change in investment recommendation based solely on this filing. Maintain a 'hold' recommendation as this event has no material impact on the company's fundamental outlook.

Keywords

Fulgent Genetics, FLGT, Paul Kim, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, 10b5-1 Plan